The Food and Drug Administration announced on Oct. 7, 2019, that Mylan Laboratories Limited voluntarily recalled Rifampin for Injection due to failed impurity specifications. The agency stated the recall addresses discoloration from elevated unknown impurities that could decrease the product's effectiveness.
How to tell if you have it
- Brand: Mylan
- Product: Rifampin for Injection, USP, 600 mg/vial
- NDC: 67457-445-60
- Lot codes: 7008334 (Exp April 2020), 7008417 (Exp Oct 2020)
- Quantity: 19,165 vials
The hazard
The recall addresses discoloration caused by elevated unknown impurity results. According to the FDA, this defect could decrease the effectiveness of the product.
Context
GovInfoNow's records show other recent recalls include Mylan Mycophenolate Mofetil Injection Recall (2026-07-02) and Mylan Mycophenolate Mofetil Injections: Failed Dissolution Specifications (2026-08-26). Additional similar product recalls listed by GovInfoNow include Mylan Prasugrel Tablets Recall (2026-08-17).